Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer
Journal for ImmunoTherapy of Cancer · 2025-07 · 13 (7) · e011948
DOI: 10.1136/jitc-2025-011948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.07.2025. Verfasst von Yifan Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tongji Hospital and School of Basic Medicine, Department of Obstetrics and Gynecology, Huazhong University of Science and Technology Tongji Medical C…. Hauptthemen laut MEDLINE: Hexokinase, Uterine Cervical Neoplasms, Antigen Presentation, Tumor-Associated Macrophages. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: "Jianbing" and "Lingyan” R&D programs of Zhejiang province, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Background
Tumor-associated macrophages (TAMs) are among the most prevalent cells within the tumor microenvironment (TME) of cervical cancer (CC). Although TAMs frequently exhibit an immunosuppressive phenotype, their plasticity enables them as an intriguing reprogrammable target for immunotherapy of CC.
Methods
Consensus clustering was employed to delineate immune infiltration patterns in a cohort of 119 patients with CC. Single-cell RNA sequencing, complemented by flow cytometry analysis, was used to characterize hexokinase 3 (HK3)-expressing cell populations. In vivo tumor models were established to assess the functional impact of HK3-expressing cells on the TME, with interventions including Hk3 knockout and CD8 + T-cell depletion. A comprehensive approach involving bulk RNA sequencing, immunoprecipitation assays, confocal microscopy imaging, and in vitro co-culture systems was implemented to elucidate the mechanisms underlying HK3 inhibition-mediated enhancement of antitumor immunity. Furthermore, the therapeutic efficacy of HK3 inhibition, both as a monotherapy and in combination with immunotherapeutic strategies, was systematically evaluated in preclinical tumor models.
Results
We elucidated a cross-regulation between TAMs and CD8 + T cells, with HK3 serving as a central regulatory node. Upon HK3 expression was upregulated by CD8 + T cells through the IFN-γ-STAT1 signaling axis, TAMs exhibited impaired cross-presentation capacity, which in turn attenuated CD8 + T cell-mediated antitumor immunity. Mechanistically, HK3 physically interacted with mechanistic target of rapamycin (mTOR), promoting nuclear translocation of transcription factor EB (TFEB) and resulting in excessive lysosomal activation and antigen degradation. Moreover, targeting HK3 in combination with immune checkpoint blockade yielded a synergistic effect in enhancing antitumor immunity.
Conclusions
Targeting HK3 in TAMs represents a promising therapeutic strategy capable of enhancing antitumor immunity and synergizing with immune checkpoint blockade by restoring efficient antigen cross-presentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tongji Hospital and School of Basic Medicine, Department of Obstetrics and Gynecology, Huazhong University of Science and Technology Tongji Medical College, Wuhan, Hubei, China.
- The Central Hospital of Wuhan, Department of Obstetrics and Gynecology, Academician Expert Workstation, Huazhong University of Science and Technology Tongji Medical College, Wuhan, Hubei, China.
- Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Zhejiang University School of Medicine Women's Hospital, Hangzhou, Zhejiang, China.
- Department of Gynecologic Oncology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, Zhejiang, China.
- Department of Pathogen Biology, Huazhong University of Science and Technology Tongji Medical College School of Basic Medicine, Wuhan, Hubei, China.
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Förderung
- "Jianbing" and "Lingyan” R&D programs of Zhejiang province
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- National Key Research and Development Program of China
- Key Technology R&D Program of Hubei
Zitieren
APA
Yang, Y., Tian, X., Chen, J., Liu, J., Jiang, H., Liu, L., Qu, S., Wu, M., Wang, J., Chen, Y., He, S., Sun, C., Huang, Y., & Wang, H. (2025). Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer. Journal for ImmunoTherapy of Cancer, 13(7), e011948. https://doi.org/10.1136/jitc-2025-011948
Vancouver
Yang Y, Tian X, Chen J, Liu J, Jiang H, Liu L, et al. Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer. Journal for ImmunoTherapy of Cancer. 2025;13(7):e011948. doi:10.1136/jitc-2025-011948
BibTeX
@article{Yang2025,
author = {Yang, Yifan and Tian, Xun and Chen, Jinglan and Liu, Jian and Jiang, Han and Liu, Liting and Qu, Shen and Wu, Min and Wang, Jingyu and Chen, Ying and He, Shan and Sun, Chaoyang and Huang, Yafei and Wang, Hui},
title = {Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {7},
pages = {e011948},
doi = {10.1136/jitc-2025-011948}
}
EUVIMED